METABOLIC AND ADIPOCYTOKINE PRECONDITIONS FOR PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS IN OBESITY PATIENTS DUE TO COMORBIDITY WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Authors

  • Olha Hryniuk HSEI of Ukraine "Bukovinian State Medical University", Ukraine,
  • Oksana Khukhlina HSEI of Ukraine "Bukovinian State Medical University", Ukraine
  • Oksana Liakhovych HSEI of Ukraine "Bukovinian State Medical University", Ukraine
  • Viktoriia Hutsuliak HSEI of Ukraine "Bukovinian State Medical University", Ukraine
  • Snizhana Hnatkovych HSEI of Ukraine "Bukovinian State Medical University", Ukraine

DOI:

https://doi.org/10.12955/pmp.v1.94

Keywords:

nonalcoholic steatohepatitis, Chronic obstructive pulmonary disease, obesity

Abstract

The increasing prevalence of chronic obstructive pulmonary disease (COPD) and nonalcoholic steatohepatitis (NASH) is a problem of high importance.

Objective: to determine the state of blood lipid spectrum, glycemia, the degree of insulin resistance and their regulation by adipose tissue hormones in NASH patients against the background of obesity, depending on comorbidity with COPD.

Methods. 130 patients were examined, including 35 NASH patients with obesity of the 1st stage (1 group), 60 NASH patients with obesity of the 1st stage and COPD 2-3 D (group 2), and 35 patients with COPD 2-3 D (group 3).

Results: Blood lipid concentration in patients of the 1st and the 2nd groups exceeded the norm by 29.5% and 39.8% respectively (p<0.05). In the 3rd group - by 14.9% (p<0.05). The content of total cholesterol in the blood also points out its probable increase by 36.3%, 45.7% and 14.9% (p<0.05) in comparison with practically healthy individuals (PHI) in patients of the 1st, 2nd and 3rd groups. A probable increase in the concentration of triacylglycerols (TG) in blood (1.9 and 2.2 times, respectively (p<0.05)) was recorded in the 1st and 2nd groups of patients, while in patients of the 3rd group the changes were quite significant (1.6 times increase, p<0.05).

Conclusions. Comorbidity of COPD in obese patients and NASH is an additional, powerful-inducing factor of lipid distress syndrome with significantly higher increase (compared with NASH without lung pathology) TG in blood, which form the basis of liver steatosis, total cholesterol, low density lipoproteins, with significantly higher decrease high density lipoproteins,  the atherogenic index, which are accompanied by hyperleptinemia, adiponectin deficiency, correlate with the degree of liver steatosis, fibrosis index, cytolytic activity, cholestatic, mesenchymal-inflammatory syndromes and are interrelated with hyperleptinemia, hypoadiponectinemia.

Author Biographies

Olha Hryniuk, HSEI of Ukraine "Bukovinian State Medical University", Ukraine,

HSEI of Ukraine "Bukovinian State Medical University", Chernivtsi, Ukraine, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases

Oksana Khukhlina, HSEI of Ukraine "Bukovinian State Medical University", Ukraine

HSEI of Ukraine "Bukovinian State Medical University", Chernivtsi, Ukraine, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases

Oksana Liakhovych, HSEI of Ukraine "Bukovinian State Medical University", Ukraine

HSEI of Ukraine "Bukovinian State Medical University", Chernivtsi, Ukraine, Department of Internal Medicine, Clinical Pharmacology and Occupational Diseases

Viktoriia Hutsuliak, HSEI of Ukraine "Bukovinian State Medical University", Ukraine

HSEI of Ukraine "Bukovinian State Medical University", Chernivtsi, Ukraine

Snizhana Hnatkovych, HSEI of Ukraine "Bukovinian State Medical University", Ukraine

HSEI of Ukraine "Bukovinian State Medical University", Chernivtsi, Ukraine

References

Anstee QM, Targher G, Day CP. (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 10(6): 330-344. doi: 10.1038/nrgastro.2013.41.

Baltieri L, Chaim EA, Chaim FDM, et al. (2018) Correlation between nonalcoholic fatty liver disease features and levels of adipokines and inflammatory cytokines among morbidly obese individuals. Arq Gastroenterol. 55(3): 247-251. doi: 10.1590/S0004-2803.201800000-62.

Dowman JK. (2011) Systematic review: the diagnosis and staging of non–alcoholic fatty liver disease and non–alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 33(5):525–540.

Elliot JG, Donovan GM, Wang KCW, et al.(2019) Fatty Airways: Implications for Obstructive Disease. Eur Respir J. https://doi.org/10.1183/13993003.00857-2019

Jung DH, Shim JY, Lee HR, et al. (2012) Relationship between non-alcoholic fatty liver disease and pulmonary function. Intern Med J. 42: 541–546.

Lazo M, Hernaez R, Eberhardt MS, et al. (2013) Prevalence of nonalcoholic fatty liver disease in the United States: The Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol. 178:38–45.

Matthews DR, Kennedy ED, Darbyshire JH, et al. (2007) The UK Diabetes Research Network - an opportunity and a challenge. Diabet Med. 24(1):7-9. DOI: 10.1111/j.1464-5491.2007.02005.x

Mykhailovska NS, Miniailenko LE. (2016) The peculiarities of adiponectin and resistin interrelationships with the components of metabolic syndrome in patients with coronary heart disease and concomitant nonalcoholic fatty liver disease. Zaporizkyi medychnyi zhurnal. 5: 25–30.

Radchenko ОМ, Pylypiv LI, Zukow V. (2017) Lung function testing according leptin levels in patients with chronic obstructive pulmonary disease. Journal of education, health and sport. 7 (З): 23l -8.

Turer AT, Scherer PE. (2012) Adiponectin: mechanistic insights and clinical implications. Diabetologia. 55(9): 2319–2326. https://doi.org/10.1007/s00125-012-2598-x

Viglino D, Jullian-Desayes I, Minoves M, et al. (2017) Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 49 (6): doi: 10.1183 / 13993003.01923-2016

Downloads

Published

2020-11-16

How to Cite

Hryniuk, O. ., Khukhlina, O. ., Liakhovych, O. ., Hutsuliak, V. ., & Hnatkovych, S. . (2020). METABOLIC AND ADIPOCYTOKINE PRECONDITIONS FOR PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS IN OBESITY PATIENTS DUE TO COMORBIDITY WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Proceedings of CBU in Medicine and Pharmacy, 1, 28-35. https://doi.org/10.12955/pmp.v1.94